Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
QURE 
Uniqure NV (QURE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: QURE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -65.5% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 484.53M USD | Price to earnings Ratio - | 1Y Target Price 36.6 |
Price to earnings Ratio - | 1Y Target Price 36.6 | ||
Volume (30-day avg) 1173686 | Beta 0.42 | 52 Weeks Range 3.73 - 19.18 | Updated Date 04/4/2025 |
52 Weeks Range 3.73 - 19.18 | Updated Date 04/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.92 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -796.27% |
Management Effectiveness
Return on Assets (TTM) -16.39% | Return on Equity (TTM) -238.46% |
Valuation
Trailing PE - | Forward PE 27.93 | Enterprise Value 225789580 | Price to Sales(TTM) 17.87 |
Enterprise Value 225789580 | Price to Sales(TTM) 17.87 | ||
Enterprise Value to Revenue 8.33 | Enterprise Value to EBITDA 0.99 | Shares Outstanding 54076900 | Shares Floating 44295995 |
Shares Outstanding 54076900 | Shares Floating 44295995 | ||
Percent Insiders 8.59 | Percent Institutions 77.61 |
Analyst Ratings
Rating 4.5 | Target Price 30.42 | Buy 2 | Strong Buy 8 |
Buy 2 | Strong Buy 8 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Uniqure NV
Company Overview
History and Background
uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Originally focused on cardiovascular gene therapy, it has evolved to focus on treatments for liver, central nervous system (CNS) and Huntington's disease.
Core Business Areas
- Liver Diseases: Developing gene therapies for liver diseases like hemophilia B and other genetic disorders of the liver.
- Central Nervous System (CNS) Disorders: Focusing on gene therapy approaches for CNS diseases, including Huntington's disease.
- Manufacturing: Providing in-house manufacturing capabilities for its gene therapy products, including vector production and fill-finish services.
Leadership and Structure
The leadership team consists of the CEO, CFO, and other senior executives. The organizational structure is based on functional departments, including research and development, manufacturing, clinical operations, and commercial operations.
Top Products and Market Share
Key Offerings
- Hemgenix: Hemgenix (etranacogene dezaparvovec) is a gene therapy for adults with hemophilia B, a bleeding disorder. In November 2022, Hemgenix was approved in the United States by the FDA. The current competition is factor IX replacement therapy (e.g., BeneFIX, Rixubis).
- AMT-130: AMT-130 is a gene therapy candidate for Huntington's disease. Phase 1/2 clinical trials are ongoing. Competitors include Wave Life Sciences and Roche/Ionis with their oligonucleotide-based therapies.
Market Dynamics
Industry Overview
The gene therapy industry is experiencing rapid growth, driven by technological advancements and increasing regulatory approvals. It's characterized by high research and development costs and potential for significant returns.
Positioning
Uniqure is a leader in the gene therapy field, with one marketed product (Hemgenix) and a promising pipeline of gene therapy candidates. They have expertise in AAV vector technology.
Total Addressable Market (TAM)
The TAM for gene therapies is estimated to be in the billions of dollars, with Hemophilia B and Huntington's disease representing significant market opportunities. uniQure's position is dependent on the success of their clinical trials and commercialization efforts.
Upturn SWOT Analysis
Strengths
- FDA-approved gene therapy (Hemgenix)
- Proprietary AAV vector technology
- In-house manufacturing capabilities
- Experienced management team
Weaknesses
- High R&D costs
- Reliance on successful clinical trial outcomes
- Commercialization challenges for gene therapies
- Limited product portfolio
Opportunities
- Expanding indications for gene therapy
- Partnering with larger pharmaceutical companies
- Acquiring complementary technologies
- Geographic expansion
Threats
- Regulatory hurdles
- Competition from other gene therapy companies
- Adverse events in clinical trials
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- BMY
- CRSP
- VIR
Competitive Landscape
uniQure's advantages include its approved gene therapy and proprietary technology. Disadvantages include high R&D costs and competition from larger companies with more resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by progress in clinical trials and regulatory approvals.
Future Projections: Future growth depends on the success of AMT-130 and other pipeline candidates, as well as commercialization of Hemgenix.
Recent Initiatives: Recent initiatives include expanding clinical trials for AMT-130 and commercializing Hemgenix.
Summary
uniQure has a strong position in the gene therapy space with an approved product (Hemgenix), but its future is highly dependent on the success of its other pipeline products like AMT-130. High R&D spending presents financial challenges. They have a potential competitive advantage with their AAV vector technology. uniQure needs to navigate pricing and reimbursement challenges to maximize the value of their therapies.
Similar Companies
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
VIR
Vir Biotechnology Inc
VIR
Vir Biotechnology Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- FDA Website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Uniqure NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2007-06-20 | CEO & Executive Director Mr. Matthew Craig Kapusta CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 209 | Website https://www.uniqure.com |
Full time employees 209 | Website https://www.uniqure.com | ||
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.